Phenazine 5,10-dioxide derivatives as hypoxic selective cytotoxins

Journal of Medicinal Chemistry

Volumn 48, Issue 1, 2005, Pages 21-23

  Cerecetto, Hugo ^a   González, Mercedes ^a   Lavaggi, Ma Laura ^a   Azqueta, Amaia ^b   López De Cerain, Adela ^b   Monge, Antonio ^b  

^a UNIVERSIDAD DE LA REPÚBLICA   (Uruguay)

^b UNIVERSITY OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

7(8) BROMO 2 AMINOPHENAZINE 5,10 DIOXIDE; 7(8) BROMO 2 HYDROXYPHENAZINE 5,10 DIOXIDE; 7(8) CHLORO 2 AMINOPHENAZINE 5,10 DIOXIDE; PHENAZINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG STRUCTURE; DRUG SYNTHESIS; HYPOXIC CELL; IN VITRO STUDY; NONHUMAN;

ANIMALS; BIOCHEMISTRY; CELL HYPOXIA; CELL LINE; CRICETINAE; CYTOTOXINS; DRUG EVALUATION, PRECLINICAL; PHENAZINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 12144272242     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0492150     Document Type: Article

References (24)

1. Jaffar, M.; Strattford, I. Bioreductive Drugs: Selectivity towards Hypoxic Tissue. Exp. Opin. Ther. Pat. 1999, 1371, 1371-1380, and references therein.
2. (b) Naylor, M. A.; Thomson, P. Recent Advances in Bioreductive Drug Targeting. Mini Rev. Med. Chem. 2001, 1, 17-29.
3. Denny, W. A.; Wilson, W. R. Bioreducible Mustards: A Paradigm for Hypoxia-Selective Prodrugs of Diffusible Cytotoxins (HPDCs). Cancer Metastasis Rev. 1993, 12, 135-151.
4. (b) Denny, W. A. Prodrug Strategies in Cancer Therapy. Eur. J. Med. Chem. 2001, 36, 577-595, and references therein.
5. (c) Brown, J. M.; Wilson, W. R. Exploiting Tumour Hypoxia in Cancer Treatment. Nature Rev. Cancer 2004, 4, 437-447.
6. Lin, A. J.; Cosby, L. A.; Shansky, C. W.; Sartorelli, A. C. Potential Bioreductive Alkylating Agents. 1. Benzoquinone Derivatives. J. Med. Chem. 1972, 15, 1247-1252.
7. (b) Cerecetto, H.; González, M. N-Oxides as Hypoxia Selective Cytotoxins. Minirev. Med. Chem. 2001, 1, 219-231, and references therein.
8. (c) Birincioglu, M.; Jaruga, P.; Chowdhury, G.; Rodríguez, H.; Dizdaroglu, M.; Gates, K. S. DNA Base Damage by the Antitumor Agent 3-Amino-1,2,4-benzotriazine 1,4-Dioxide (Tirapazamine). J. Am. Chem. Soc. 2003, 125, 11607-11615.
9. Brown, J. M. SR 4233 (Tirapazamine): A New Anticancer Drug Exploiting Hypoxia in Solid Tumours. Br. J. Cancer 1993, 67, 1163-1170.
10. Patterson, L. H. Rationale for the use of Aliphatic N-Oxides of Cytotoxic Anthraquinones as Prodrug DNA Binding Agents: A New Class of Bioreductive Agent. Cancer Met. Rev. 1993, 12, 119-134.
11. (b) Lee, H. H.; Wilson, W. R.; Ferry, D. M.; van Zijl, P.; Pullen, S. M.; Denny, W. A. Hypoxia-Selective Antitumor Agents. 13. Effects of Acridine Substitution on the Hypoxia-Selective Cytotoxicity and Metabolic Reduction of the Bisbioreductive Agent Nitracrine N-Oxide. J. Med. Chem. 1998, 39, 2508-2517.
12. Monge, A.; Palop, J. A.; López de Ceráin, A.; Senador, V.; Martínez-Crespo, F. J.; Sáinz, Y.; Narro, S.; García, E.; de Miguel, C.; González, M.; Barker, A. J.; Hamilton, E.; Barker, A. J.; Clarke, E. D.; Greenhow, D. T. Hypoxia-selective Agents Derived from Quinoxaline 1,4-Di-N-oxides. J. Med. Chem. 1995, 38, 1786-1792.
13. (b) Boiani, M.; Cerecetto, H.; González, M.; Risso, M.; Olea-Azar, C.; Piro, O. E.; Castellano, E. E.; López de Ceráin, A.; Ezpeleta, O.; Monge, A. 1,2,5-Oxadiazole N-Oxide Derivatives as Potential Anti-Cancer Agents: Synthesis and Biological Evaluation. Part IV. Eur. J. Med. Chem. 2001, 36, 771-782.
14. (c) Boiani, M.; Cerecetto, H.; González, M. Cytotoxicity of Furoxans: Quantitative Structure - Activity Relationships Study. Farmaco 2004, 59, 405-412.
15. Nagai, K.; Carter, B. J.; Xu, J.; Hecht, S. M. DNA Cleavage by Oxygen Radicals Produced in the Absence of Metal Ions or Light. J. Am. Chem. Soc. 1991, 113, 5099-5100.
16. (b) Helissey, P.; Giorgi-Renault, S.; Colson, P.; Houssier, C.; Bailly, C. Sequence-Recognition and Cleavage of DNA by a Netropsin-phenazinedi-N-oxide Conjugate. Bioconjugate Chem. 2000, 11, 219-227.
17. (c) Laursen, J. B.; Nielsen, J. Phenazine Natural Products: Biosynthesis, Synthetic Analogues, and Biological Activity. Chem. Rev. 2004, 104, 1663-1685.
18. Abu El-Haj, M. J.; Dominy, B. W.; Johnston, J. D. New Route to Phenazine 5, 10-Dioxides and Related Compounds. J. Org. Chem. 1972, 37, 589-593.
19. (b) Edwards, M. L.; Bambury, R. E. 2,3-Dimethylquinoxaline-6- carboxaldehyde 1,4-Dioxide. J. Heterocycl. Chem. 1975, 12, 835-836.
20. (c) Ludwig, G.-W.; Baumgartel, H. Isomerenbildung bei der Umsetzung von Benzofurazan-N-oxiden mit Phenolat-Anionen. Chem. Ber. 1982, 115, 2380-2383.
21. Boulton, A. J.; Katritzky, A. R.; Sewell, M. J.; Wallis, B. N-Oxides and Related Compounds. XXXI. The Nuclear Magnetic Resonance Spectra and Tautomerism of some Substituted Benzofuroxans. J. Chem. Soc. B 1967, 9, 914-917.
22. (b) Boulton, A. J.; Halls, P. J.; Katritzky, A. R. N-Oxides and Related Compounds. Part XXXVII. The Effect of Methyl and Aza-substituents on the Tautomeric Equilibrium in Benzofuroxan. J. Chem. Soc. B 1970, 636-640.
23. See Supporting Information.
24. Issidorides, C. H.; Haddadin, M. J. Benzofurazan Oxide. II. Reactions with Enolate Anions. J. Org. Chem. 1966, 31, 4067-4068.